PPiP2: Prevalence of Pathogenic Antibodies in Psychosis

*COVID-19 UPDATE: This study has been paused.*

This study aims to estimate the prevalence of antibodies against neuronal cell surface targets in patients with psychotic symptoms. This is done by taking a blood sample and analysing it for the presence of these antibodies.

There is a short questionnaire and some blood will be collected. Participants will be given £10 for their time.

To take part you must:

  • Be aged between 18-70.
  • Have acute psychosis symptoms: lasting for at least the past two weeks but    no longer than two years.
  • Patients can have a total history of psychosis longer than 2 years, as long as there has been a period of at least six months of remission prior to the current episode. The current episode should be less than 2 years long.

NOTE: You cannot take part if any of the following apply:

  • Any other neurological disorders including multiple sclerosis, epilepsy, cerebrovascular disease, hydrocephalus, traumatic brain injury, meningo-encephalitis, systemic lupus erythematosus, CNS vasculitis.
  • Primary drug induced psychosis
  • Pregnancy.

If you would like to take part or want more information please contact the study lead:

Study Contact: Joanne McCarthy

Email: joanne.mccarthy@southernhealth.nhs.uk

Tel: 02380 475943

Accessibility tools

Return to header